Short supply of Terramycin exposes weak spot of the pharmaceutical notification system

“If a top product of a specific prescription market is not supplied for a year, it must be considered not as out-of-stock, but manufacturing suspension.”

It is a part of the opinions towards the short supply of Pfizer’s Terramycin Eye Oint

Most of all, the biggest problem is that the drug, which has strong control in the market, is not a product which needs to be reported for the long-term sh...